{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "2839579",
  "DateCompleted": {
    "Year": "1988",
    "Month": "08",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "05",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0022-1899",
      "JournalIssue": {
        "Volume": "158",
        "Issue": "1",
        "PubDate": {
          "Year": "1988",
          "Month": "Jul"
        }
      },
      "Title": "The Journal of infectious diseases",
      "ISOAbbreviation": "J Infect Dis"
    },
    "ArticleTitle": "Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults.",
    "Pagination": {
      "StartPage": "166",
      "EndPage": "175",
      "MedlinePgn": "166-75"
    },
    "Abstract": {
      "AbstractText": [
        "We performed two studies to determine the dose-related tolerance and the efficacy of recombinant beta serine interferon (rIFN-beta ser) in experimental rhinovirus infection. In the tolerance study, 120 healthy adults received intranasal sprays of rIFN-beta ser or placebo daily for 25 d. No differences in nasal symptoms were found. Rhinoscopy detected more mucosal bleeding sites in high-dose (38%) versus low-dose (12.5%) or placebo (12.5%) recipients. There were more subepithelial lymphocytes in nasal biopsy specimens in the high-dose (54%) than the low-dose (17%) or placebo (17%) groups. In the efficacy study, 34 volunteers received daily nasal drops of IFN, beginning 36 h before challenge and for three days afterwards. The numbers of infections and days of shedding of virus were not reduced, but colds occurred less often in the high-dose (25%) than in the low-dose (55%) or placebo (64%) recipients. Nasal mucus weights were lower in the high-dose (mean +/- SD g per five days; 5 +/- 4) than placebo (31 +/- 37) recipients. Thus, rIFN-beta ser may have a more favorable therapeutic ratio than do previously tested alpha interferons."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville."
          }
        ],
        "LastName": "Sperber",
        "ForeName": "S J",
        "Initials": "SJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Levine",
        "ForeName": "P A",
        "Initials": "PA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Innes",
        "ForeName": "D J",
        "Initials": "DJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mills",
        "ForeName": "S E",
        "Initials": "SE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hayden",
        "ForeName": "F G",
        "Initials": "FG"
      }
    ],
    "GrantList": [
      {
        "GrantID": "T32AI-07046",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't",
      "Research Support, U.S. Gov't, P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Infect Dis",
    "NlmUniqueID": "0413675",
    "ISSNLinking": "0022-1899"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interferon Type I"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Proteins"
    },
    {
      "RegistryNumber": "145155-23-3",
      "NameOfSubstance": "Interferon beta-1b"
    },
    {
      "RegistryNumber": "77238-31-4",
      "NameOfSubstance": "Interferon-beta"
    },
    {
      "RegistryNumber": "XRO4566Q4R",
      "NameOfSubstance": "Interferon beta-1a"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Intranasal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "microbiology",
        "pathology",
        "prevention & control"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Evaluation Studies as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Interferon Type I"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Interferon beta-1a"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Interferon beta-1b"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Interferon-beta"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Lymphocytes"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "pathology"
      ],
      "DescriptorName": "Nasal Mucosa"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Patient Acceptance of Health Care"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Recombinant Proteins"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Self Administration"
    }
  ]
}